BPC-157 systemic vs local effects — September 2026

roxy_nash said:

PK/PD modeling for the pharmacology: understanding the pharmacokinetics helps optimize dosing.

That reframing is the part I needed. Sending this to two other people who asked me the same thing last week.

Clinical perspective, offered as context rather than as advice. Take it one variable at a time. Almost every unanswerable question in these threads is unanswerable because three things changed in the same fortnight, and no amount of subsequent argument can untangle them after the fact.

That is the short version; the long version is somebody else's post.

lisa_labSD said:

Amycretin (AMY/GLP-1 dual agonist) emerging data relevant to the pharmacology: Phase 1 showed -13.1% body weight at only 12 weeks, the fastest…

Careful with the causal language. Two things moving together in a period when five things changed is not a mechanism, and stating it as one makes the thread less useful to somebody reading it later.

Correct me if the detail matters more than I have assumed.

One concrete data point for the thread. The boring version of this is the one that works, and the boring version is: measure a baseline, change one variable, wait, measure again under the same conditions. Nobody wants that answer and it is still the answer.

If somebody has the primary source to hand I would rather cite it than paraphrase it.

Moderator note: a couple of off-topic posts removed. No action needed from anybody.